Lead program: Preclinical

Alexander Shulgin Research Institute

Also known as: ASRI

Data updated June 27, 2026

3 Drug Candidates

The Alexander Shulgin Research Institute (ASRI) was founded in 2021 by Dr. Nicholas Cozzi, Dr. Paul Daley, and the late Ann Shulgin, continuing the legacy of chemist Alexander Shulgin. The institute maintains the Shulgin Vault — a repository of over 500 compounds synthesized by Shulgin and ASRI scientists. Lead candidate ASR-3001 (5-MeO-iPALT) is an orally active, fast-acting tryptamine with a mild internal psychedelic profile and no visual hallucinations, near IND-ready for psychiatric disorders. ASR-2001 is a non-hallucinogenic compound producing mental clarity.

Pipeline Intelligence

Developer Momentum

Programme tracker

Active candidates: 3
Active programmes: 3
Lead stage: Preclinical
Forecast coverage: 3 of 3

Latest sourced update

ASRI latest-news archive notes $7.2M seed financing round

Jun 27, 2026 - company-website - Alexander Shulgin Research Institute - ASR-3001 (5-MeO-iPALT)

Next known catalyst

Regulatory filing submitted

Timing not specified - ASR-3001 (5-MeO-iPALT) / ASR-3001 IND-Enabling Programme (Depression/Anxiety) - Confidence: 40%

6 sources0 pipeline-linked trials0 pipeline-linked papers2 Preclinical1 Discovery

Development Programmes

ASR-3001 (5-MeO-iPALT)

5-MeO-DMT

Preclinical

Major Depressive Disorder (MDD)Anxiety Disorders

Depression / anxiety — fast-acting tryptamine producing internal psychedelic state without sensory disturbance

Programme Tracker

Major Depressive Disorder (MDD)

Primary: US (FDA)

Pre-clinicalActive

Forecast

Regulatory filing submitted

ASRI continues to describe ASR-3001 as its advanced tryptamine candidate, supported by 2024 patent filings. No public IND filing was found in this pass.

Milestones

Funding milestone

Completed

Actual: Dec 9, 2021

ASRI news archive confirms the $7.2M seed financing round on December 9, 2021; prior late-2024 placeholder date was corrected during Wave 24.

Why it matters: The Noetic Fund-led $7.2M seed provides runway for IND-enabling studies. ASRI is uniquely positioned with access to the Shulgin compound library — thousands of novel psychoactive compounds from the most prolific psychedelic chemist in history.

ASRI latest-news archive notes $7.2M seed financing round(company-website)[Verified]

Company milestone

Completed

Actual: Jun 1, 2023

Scientific Advisory Board formed; ASR-3001 and ASR-2001 identified as lead compounds at Psychedelic Science 2023

Why it matters: ASRI was founded on Bicycle Day 2021 by Ann Shulgin, Paul Daley, and Nicholas Cozzi to continue Alexander Shulgin's legacy with modern drug development. The SAB formation and lead compound selection at PS2023 marked the transition from IP curation to active development.

(Press release)[Verified]

Company milestone

Completed

Actual: May 1, 2024

International patent filings for empathogens, tryptamines, and phenylalkylamines; ASR-3001 described as "on the threshold" of IND filing

Why it matters: Patent filings across multiple compound classes protect the commercial value of the Shulgin library. The "threshold" IND language suggests preclinical tox work is near-complete for ASR-3001, though no filing has been confirmed.

Watch next: IND filing confirmation and Phase 1 FIH study initiation

ASRI Expands Global Reach with Patent Filings(Press release)[Verified]ASRI Expands Global Reach with Patent Filings(Press release)[Verified]

Licensing deal

Completed

Actual: Dec 1, 2024

Negev Labs licensing agreement for ASRI compound library — gives Negev access to develop compounds from the Shulgin collection

Why it matters: The Negev Labs licensing deal (announced alongside Negev's emergence from stealth and Beckley Psytech asset acquisition) creates a parallel development pathway for ASRI compounds. Generates licensing revenue for ASRI while expanding the reach of the Shulgin library.

(Press release)[Verified]

Company milestone

Completed

Actual: Mar 1, 2025

Leadership transition — Paul Daley succeeds Nicholas Cozzi as ASRI president

Why it matters: Leadership change may reflect strategic shift or normal succession. Daley is an ASRI co-founder with deep Shulgin library expertise.

ASRI Latest News - ASR-3001 and Patent Filings(company-website)[Verified]

Recorded Events

Mar 1, 2025: Company milestone

Dec 1, 2024: Licensing deal

May 1, 2024: Company milestone

Jun 1, 2023: Company milestone

Dec 9, 2021: Funding milestone

Evidence Links

ASRI Latest News - ASR-3001 and Patent Filings

company-website - Alexander Shulgin Research Institute - Jun 26, 2026 - Verified

ASRI news page tracks its 2024 patent filings and development updates, including ASR-3001.

ASRI Expands Global Reach with Patent Filings

Press release - PRNewswire / ASRI - May 28, 2024 - Verified

ASRI describes ASR-3001 as a short-acting orally active tryptamine with an internal psychedelic cognitive state and limited sensory involvement.

ASRI latest-news archive notes $7.2M seed financing round

company-website - Alexander Shulgin Research Institute - Jun 27, 2026 - Verified

Company news archive reviewed June 27, 2026; archive lists December 9, 2021: ASRI raises $7.2 million in seed financing round.

ASR-2001 (2CB-5PrO)

Preclinical

Non-hallucinogenic phenethylamine-based 5-HT2A agonist — preclinical

Programme Tracker

ASR-2001 Preclinical Programme

Primary: US (FDA)

Pre-clinicalActive

Forecast

preclinical-data

Preclinical phenylalkylamine work remains supported by ASRI 2024 patent filings and news updates; no clinical trial registration was found in this pass.

Evidence Links

ASRI Latest News - Phenylalkylamine Programme

company-website - Alexander Shulgin Research Institute - Jun 26, 2026 - Verified

ASRI news page reports 2024 updates for phenylalkylamine discoveries and related patent filings.

ASRI Patent Filings for Phenylalkylamines

Press release - PRNewswire / ASRI - May 28, 2024 - Verified

Patent announcement supports ASRI phenylalkylamine development relevant to ASR-2001 / 2CB-5PrO.

XOB

Discovery

Bipolar Disorder

Bipolar disorder — bifunctional 5-HT2A antagonist / sodium channel blocker

Programme Tracker

Bipolar Disorder

Primary: US (FDA)

DiscoveryActive

Forecast

preclinical-data

XOB remains a discovery-stage bipolar disorder programme, supported by ASRI 2024 announcement and peer-reviewed pharmacology characterisation.

Milestones

Discovery started

Completed

Actual: May 1, 2024

ASRI announced XOB — a bifunctional 5-HT2A antagonist and sodium channel blocker — as a novel bipolar disorder candidate from the Shulgin library

Why it matters: XOB combines two validated mechanisms (5-HT2A antagonism used in atypical antipsychotics; sodium channel blockade used in mood stabilisers like lamotrigine) in a single molecule. If the bifunctional profile translates to efficacy with fewer side effects, it could be a novel approach to bipolar treatment.